SCHEMBL3053077

SCHEMBL3053077

O=C(Cc1cccc2ccccc12)OCc1cccs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.61
▸ ALDH1A1 P00352 4/20 0.61
▸ LMNA P02545 3/20 0.61
▸ MEN1 O00255 3/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ POLB P06746 2/20 0.61
▸ HPGD P15428 1/20 0.61
▸ BLM P54132 1/20 0.61
▸ MAPT P10636 3/20 0.51
▸ NR2F2 P24468 1/20 0.51
▸ THRB P10828 1/20 0.50
▸ TDP1 Q9NUW8 2/20 0.49
▸ HTT P42858 2/20 0.46
▸ PKM P14618 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ SIRT5 Q9NXA8 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ MAPK8 P45983 2/20 0.44
▸ MAPK9 P45984 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054334 0.89 MEN1 (0.65) L3MBTL1ALDH1A1LMNAMEN1KMT2A
SCHEMBL3044895 0.79 CASP1 (0.62) L3MBTL1ALDH1A1LMNAMEN1KMT2A
SCHEMBL3045682 0.78 L3MBTL1 (0.60) L3MBTL1ALDH1A1LMNAMEN1KMT2A
SCHEMBL21693940 0.76 TDP1 (0.61) L3MBTL1ALDH1A1LMNAMEN1KMT2A
SCHEMBL11304824 0.76 TDP1 (0.61) L3MBTL1ALDH1A1LMNAMEN1KMT2A
SCHEMBL23094223 0.76 L3MBTL1 (1.00) L3MBTL1ALDH1A1LMNAMEN1KMT2A
SCHEMBL845701 0.75 KMT2A (0.62) L3MBTL1ALDH1A1LMNAKMT2AHPGD
SCHEMBL29729685 0.75 KMT2A (0.62) L3MBTL1ALDH1A1LMNAKMT2AHPGD
SCHEMBL590845 0.74 TDP1 (0.67) L3MBTL1ALDH1A1LMNAMEN1KMT2A
SCHEMBL3409571 0.74 NPC1 (0.56) L3MBTL1ALDH1A1LMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8647878-B2 Highly refractive immersion liquids and their use CARL ZEISS AG (DE) 2014-02-11 — — US disclosed
US-8647878-B2 Highly refractive immersion liquids and their use CARL ZEISS AG (DE) 2014-02-11 — — US disclosed
US-8647878-B2 Highly refractive immersion liquids and their use CARL ZEISS AG (DE) 2014-02-11 — — US disclosed
US-20100212547-A1 Highly Refractive Immersion Liquids And Their Use CARL ZEISS AG (DE) 2010-08-26 — — US disclosed
US-20100212547-A1 Highly Refractive Immersion Liquids And Their Use CARL ZEISS AG (DE) 2010-08-26 — — US disclosed
US-20100212547-A1 Highly Refractive Immersion Liquids And Their Use CARL ZEISS AG (DE) 2010-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100212547-A1 Highly Refractive Immersion Liquids And Their Use NR4A3, NR2E3, NR4A1 L3MBTL1 2996/4885ALDH1A1 3757/4885LMNA 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback